Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2023 Earnings Call Transcript

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2023 Earnings Call Transcript May 6, 2023

Operator: Good day and thank you for standing by and welcome to the Kiniksa Pharmaceuticals First Quarter 2023 Earnings Conference Call. [Operator Instructions] And please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Rachel Frank, Head, Investor Relations. Please go ahead.

Rachel Frank: Thank you, operator. Good morning, everyone and thank you for joining Kiniksa’s call to discuss our first quarter 2023 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the Investors & Media section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. Ross Moat, our Chief Commercial Officer, will provide an update on our outlook commercial execution. Then Mark Ragosa, our Chief Financial Officer, will review our first quarter 2023 financial results. And finally, Sanj will return for closing remarks and to kick off the Q&A session for which Eben Tessari, our Chief Operating Officer; and John Paolini, our Chief Medical Officer, will also be on the line.

Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide as well under the caption risk factors contained in our SEC filings. These statements speak only as of the date of this presentation and we undertake no obligation to update such statements, except as required by law. With that, I will turn it over to Sanj.

Sanj Patel: Thanks, Rachel and good morning, everyone. I’m happy to review our first quarter 2023 financial results today. We have continued to execute across our cardiovascular and autoimmune franchises which positions us for success and growth in 2023. On the commercial side, Q1 represented another quarter of growth for ARCALYST with a net product revenue of $42.7 million. We are encouraged by our commercial execution to date. And with recent increased prescriber adoption and patient enrollments, we’re seeing clear signs of success from our field team expansion. We’ve also continued to see high patient satisfaction, strong payer approval rates as well as longer duration of therapy. With that in mind, we have raised our 2023 expected ARCALYST guidance range to $200 million to $215 million.

We also remain focused on building the maximum value across our portfolio of clinical stage assets and that includes KPL-404 which is our CD40 antagonist program. We’re currently enrolling the third and final cohort of our Phase II study in rheumatoid arthritis which is designed to evaluate the efficacy, dose response, PK and safety of chronic subcu dosing over a duration of 12 weeks. And we expect data from this study in the first half of next year. Additionally, we continue to pursue collaborative study agreements with mavrilimumab to evaluate its potential in rare cardiovascular diseases. This is a molecule that we continue to be excited about and it has the potential to impact a number of diseases. So with that, I’ll turn it over to Ross to review our commercial execution for ARCALYST.

Ross?

Ross Moat: Thank you, Sanj. ARCALYST has now been on the market for 2 years and I’m delighted to share further details on our first quarter 2023 commercial performance and our plans for continued growth in recurrent pericarditis. We’ve been very encouraged by the meaningful acceleration in Q1 in both total and repeat prescribers in large part due to our expanded field force. Total prescribers since the launch of ARCALYST in recurrent pericarditis and now in excess of 1,000 which is a growth of more than 200 versus Q4 and is the largest jump we’ve seen to date. Additionally, repeat prescribers grew to 23% of the much larger total prescriber base. The underlying patient growth seen in Q1 drove a net revenue of $42.7 million, representing approximately 7% growth versus the prior quarter.

Our revenue growth is despite the Q1 seasonal related impacts to insurance plan changes and resets of copays which are very typical for specialty drugs in the first quarter of the year. These impacts resulted in a gross to net of 10.7% which is higher than in prior quarters. In addition to growing prescriber adoption, we’re also continuing to see high reported prescriber and patient satisfaction and strong compliance and adherence when patients are on therapy. I’ll also highlight that the payer approval rate in Q1 remains greater than 90% of all completed cases as it has been every single quarter since launch. Moving to Slide 8. Our commercial launch is focused on building the market and establishing ARCALYST as the standard of care in recurrent pericarditis.

In the 2 years since launch, we’ve gained several insights which have helped inform our tactics. Some of those learnings led to the expansion of our field team from around 30 to around 50 representatives during Q4 of 2022. I’m pleased to share that in the early days of this expansion, our field team are executing well. So far, we’re seeing a significant jump in total activity and increased reach and frequency with our target doctors. And as a result of those metrics, we’re seeing an acceleration in the total prescriber base and a more meaningful jump in overall patient enrollments than we’ve previously seen. We believe these are all early indications of the type of impact we need to be making in the marketplace to continue to advance our business and help many more patients suffering from this debilitating disease.

In addition to the essence of our sales team, there is an increase in interest as a growing number of both private and academic institutions across the U.S. to build their own referral networks and to streamline patients’ access to centers and health care professionals who focus on the treatment of pericardial diseases, in particular recurrent pericarditis. We believe this growth and expertise specific to recurrent pericarditis will help improve patient care in the future. Additionally, we’re continuing to make inroads into digital marketing, having built a database of approximately 4,500 pericarditis patients and caregivers where we are advancing education to patients themself advocates for ARCALYST when appropriate. Turning to Slide 9. I’d like to provide an update on duration of therapy.

As we follow more patients over longer periods of time in the commercial setting, we’ve seen an evolving picture in the average total duration of therapy. We have previously seen an average of approximately 18 months and now the latest data we’ve seen an increase to approximately 20 months. What we’re currently seeing is patients are initially staying on treatment for around 14 months before trial and stop. This is an increase of 2 months over what we saw at the end of Q4. Then once patients stop treatment, given the persistence of the disease, many have seen an unmasking of the disease with a return of symptoms until they restart ARCALYST. In fact, approximately 45% of all patients who stop ARCALYST do want to restart the vast majority within 8 weeks of the stop.

These factors will continue to evolve the total duration of the treatment and our efforts are placed on educating physicians and patients on the natural history of the disease which is a median of 3 years. And the continued treatment with ARCALYST results in continued treatment response. We continue to be delighted with our ongoing commercialization efforts, including the early results from our expanded field team. These results, along with the feedback that we’re getting from physicians and patients, the growth in the prescriber rates, the strong payer approval dynamics and the growth in total duration of therapy, mean that today, we are increasing our 2023 ARCALYST sales guidance from a range of $190 million to $205 million to $200 million to $215 million.

We continue to have a growing profitable collaboration with ARCALYST as well as a significant opportunity ahead as we build and develop the marketplace. Two years post approval; we are in a brilliant condition. With that said, we’re highly ambitious and we now continue to do what we do best which is driving the opportunity and solidly executing to grow our business and help patients. I’ll now hand over to Mark to cover our financial results. Mark?

Mark Ragosa: Thanks, Ross. Good morning, everyone. Our detailed first quarter 2023 financial results can be found in the press release we issued earlier today. I’d like to call your attention to a few items on this slide as well as review our 2023 ARCALYST net product revenue guidance. First, total revenue in the first quarter of 2023 was $48.3 million compared to $32.2 million in the first quarter of 2022. Total revenue in the first quarter of 2023 included ARCALYST net product revenue of $42.7 million and collaboration revenue of $5.7 million from our vixarelimab global license agreement with Genentech. To date, we have recognized close to $94 million of the $100 million upfront and near-term supply payments received from Genentech.

We expect to recognize the balance over the course of the next year. Second, ARCALYST collaboration operating profit continued to grow in the first quarter of 2023 and was $16.6 million compared to $4.5 million in the first quarter of 2022. Third, Kiniksa’s net loss in the first quarter of 2023 was $12.3 million compared to $25.2 million in the first quarter of 2022. Fourth, we received a $20 million supply-related milestone from Genentech in the first quarter and this inflow limited our net cash burn to approximately $3 million and brought our end-of-period cash balance to $187.5 million. Importantly, these reserves as well as continued ARCALYST commercial execution are expected to fund our current operating plan into at least 2026. Lastly, turning to our financial guidance.

With an uptick in enrollment in new-to-brand patients from the recent sales force expansion as well as slightly longer average duration of therapy, we now expect 2023 ARCALYST net product revenue of between $200 million and $215 million. This represents close to 70% year-over-year net product revenue growth at the midpoint and reflects our expectation for continued execution against our opportunity to help recurrent pericarditis patients by reshaping the treatment paradigm with ARCALYST. With that, I’ll turn the call back to Sanj for closing remarks.

Sanj Patel: Thanks, Mark. As you’ve heard today and the team has a lot to be excited about in terms of the summary. In addition to our successful commercialization of ARCALYST, we also have a pipeline of mid-stage clinical programs that are aimed at making a meaningful impact on patient wise. As a reminder, we’re rolling in the third and final cohort of the Phase II study of KPL-404 in rheumatoid arthritis and that date is expected in the first half of next year. Importantly, as Mark just reviewed, we are well capitalized. Thanks to those growing ARCALYST revenues, non-diluted capital from strategic out-license transactions and our continued financial discipline, we now, as Mark said, have our expected cash runway into at least 2026.

Ultimately, our mission is to continue to help patients in need create massive value and make a generational impact. We believe we are strategically positioned to do exactly that. I do want to thank you all for your time today. I’m going to hand it back to the operator for the Q&A session. Thank you.

Q&A Session

Follow Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA)

Operator: [Operator Instructions] Your first question comes from the line of Paul Choi of Goldman Sachs.

Operator: Your next question comes from the line of Geoff Meacham of Bank of America.

Operator: And there are no further questions. I would now like to turn the conference back to Sanj Patel, Chief Executive Officer.

Sanj Patel: No, great. Thank you, everybody, for the questions and joining us on the call today. We clearly have an exciting year ahead of us and very much looking forward to providing additional updates in the future. So with that, have a great day. Thank you.

Operator: This concludes today’s conference call. Thank you for participating and you may now disconnect.

Follow Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA)

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…